New study updates evidence on rare blood-clotting condition after covid-19 vaccination
Based on health data from five European countries and the US, it shows a small increased risk of TTS after a first dose of the Oxford-AstraZeneca vaccine, and a trend towards an increased risk after the Janssen/Johnson & Johnson vaccine, compared with the Pfizer-BioNTech vaccine.
A study sheds further light on the risk of developing thrombosis with thrombocytopenia syndrome (TTS) after vaccination against the covid-19 virus.
www.bmj.com